Fused compounds that inhibit vanilloid subtype 1 (VR1) receptor

1. A method of treating a disorder by inhibiting vanilloid receptor subtype 1 in a mammal wherein the disorder is selected from the group consisting of pain, bladder overactivity, urinary incontinence, and inflammatory thermal hyperalgesia, comprising administering a therapeutically effective amount of a compound of formula (I) or a pharmaceutically acceptable salt or prodrug thereof

wherein

--- is a single bond;

X 1 is N or CR 1 ;

X 2 is N or CR 2 ;

X 3 is N, NR 3 , or CR 3 ;

X 4 is N or CR 4 ;

X 5 is N or C;

provided that at least one of X 1 , X 2 , X 3 , and X 4 is N;

Z 1 is O, NH, or S;

Z 2 is a bond, NH, or O;

Ar 1 is dihydro-1H-indenyl, 1H-indenyl, tetrahydronaphthalenyl, or dihydronaphthalenyl, wherein the Ar 1 group is optionally substituted with 1, 2, 3, 4, or 5 substituents independently selected from alkenyl, alkoxy, alkoxyalkoxy, alkoxyalkyl, alkoxycarbonyl, alkoxycarbonylalkyl, alkyl, alkylcarbonyl, alkylcarbonylalkyl, alkylcarbonyloxy, alkylthio, alkynyl, carboxy, carboxyalkyl, cyano, cyanoalkyl, formyl, formylalkyl, haloalkoxy, haloalkyl, haloalkylthio, halogen, hydroxy, hydroxyalkyl, mercapto, mercaptoalkyl, nitro, (CF 3 ) 2 (HO)C—, —NR A S(O) 2 R B , —S(O) 2 OR A , —S(O) 2 R B , —NZ A Z B , (NZ A Z B )alkyl, (NZ A Z B )carbonyl, (NZ A Z R )carbonylalkyl, or (NZ A Z B )sulfonyl, wherein Z A and Z B are each independently hydrogen, alkyl, alkylcarbonyl, formyl, aryl, or arylalkyl;

R 1 , R 3 , R 5 , R 6 , and R 7 are each independently hydrogen, alkenyl, alkoxy, alkoxyalkoxy, alkoxyalkyl, alkoxycarbonyl, alkoxycarbonylalkyl, alkyl, alkylcarbonyl, alkylcarbonylalkyl, alkylcarbonyloxy, alkylthio, alkynyl, carboxy, carboxyalkyl, cyano, cyanoalkyl, cycloalkyl, cycloalkylalkyl, formyl, formylalkyl, haloalkoxy, haloalkyl, haloalkylthio, halogen, hydroxy, hydroxyalkyl, mercapto, mercaptoalkyl, nitro, (CF 3 ) 2 (HO)C—, —NR A S(O) 2 R B , —S(O) 2 OR A , —S(O) 2 R B , —NZ A Z B , (NZ A Z B )alkyl, (NZ A Z B )carbonyl, (NZ A Z B )carbonylalkyl or (NZ A Z B )sulfonyl;

R 2 and R 4 are each independently hydrogen, alkenyl, alkoxy, alkoxyalkoxy, alkoxyalkyl, alkoxycarbonyl, alkoxycarbonylalkyl, alkyl, alkylcarbonyl, alkylcarbonylalkyl, alkylcarbonyloxy, alkylthio, alkynyl, carboxy, carboxyalkyl, cyano, cyanoalkyl, cycloalkyl, cycloalkylalkyl, formyl, formylalkyl, haloalkoxy, haloalkyl, haloalkylthio, halogen, hydroxy, hydroxyalkyl, mercapto, mercaptoalkyl, nitro, (CF 3 ) 2 (HO)C—, —NR A S(O) 2 R B , —S(O) 2 OR A , —S(O) 2 R B , —NZ A Z B , (NZ A Z B )alkyl, (NZ A Z B )alkylcarbonyl, (NZ A Z B )carbonyl, (NZ A Z B )carbonylalkyl, (NZ A Z B )sulfonyl, (NZ A Z B )C(═NH)—, (NZ A Z B )C(═NCN)NH—, or (NZ A Z B )C(═NH)NH—;

R A is hydrogen or alkyl;

R B is alkyl, aryl, or arylalkyl;

R 8a is hydrogen or alkyl; and

R 8b is absent, hydrogen, alkoxy, alkoxycarbonylalkyl, alkyl, alkylcarbonyloxy, alkylsulfonyloxy, halogen, or hydroxy;

provided that R 8b is absent when X 5 is N.

2. The method according to claim 1 wherein the disorder is pain.

3. The method according to claim 1 wherein the disorder is bladder overactivity.

4. The method according to claim 1 wherein the disorder is urinary incontinence.

5. The method according to claim 1 wherein the disorder is inflammatory thermal hyperalgesia.

6. A pharmaceutical composition comprising a therapeutically effective amount of a compound of formula (I) or a pharmaceutically acceptable salt or prodrug thereof

wherein

--- is absent or a single bond;

X 1 is N or CR 1 ;

X 2 is N or CR 2 ;

X 3 is N, NR 3 or CR 3 ;

X 4 is a bond, N, or CR 4 ;

X 5 is N or C;

provided that at least one of X 1 , X 2 , X 3 and X 4 is N;

Z 1 is O, NH, or S;

Z 2 is NH or O;

Ar 1 is dihydro-1 H-indenyl, 1 H-indenyl, tetrahydronaphthalenyl, or dihydronaphthalenyl, wherein the Ar 1 group is optionally substituted with 1, 2, 3, 4, or 5 substituents independently selected from alkenyl, alkoxy, alkoxyalkoxy, alkoxyalkyl, alkoxycarbonyl, alkoxycarbonylalkyl, alkyl, alkylcarbonyl, alkylcarbonylalkyl, alkylcarbonyloxy, alkylthio, alkynyl, carboxy, carboxyalkyl, cyano, cyanoalkyl, formyl, formylalkyl, haloalkoxy, haloalkyl, haloalkylthio, halogen, hydroxy, hydroxyalkyl, mercapto, mercaptoalkyl, nitro, (CF 3 ) 2 (HO)C—, —NR A S(O) 2 R B , —S(O) 2 OR A , —S(O) 2 R B , —NZ A Z B , (NZ A Z B )alkyl, (NZ A Z B )carbonyl, (NZ A Z B )carbonylalkyl, or (NZ A Z B )sulfonyl, wherein Z A and Z B are each independently hydrogen, alkyl, alkylcarbonyl, formyl, aryl, or arylalkyl;

R 1 , R 3 , R 5 , R 6 , R 7 are each independently hydrogen alkenyl, alkoxy, alkoxyalkoxy, alkoxyalkyl, alkoxycarbonyl, alkoxycarbonylalkyl, alkyl, alkylcarbonyl, alkylcarbonylalkyl, alkylcarbonyloxy, alkylthio, alkynyl, carboxy, carboxyalkyl, cyano, cyanoalkyl, cycloalkyl, cycloalkylalkyl, formyl, formylalkyl, haloalkoxy, haloalkyl, haloalkylthio, halogen, hydroxy, hydroxyalkyl, mercapto, mercaptoalkyl, nitro, (CF 3 ) 2 (HO)C—, —NR A S(O) 2 R B , —S(O) 2 OR A , —S(O) 2 R B , —NZ A Z B , (NZ A Z B )alkyl, (NZ A Z B )carbonyl, (NZ A Z B )carbonylalkyl, or (NZ A Z B )sulfonyl;

R 2 and R 4 are each independently hydrogen, alkenyl, alkoxy, alkoxyalkoxy, alkoxyalkyl, alkoxycarbonyl, alkoxycarbonylalkyl, alkyl, alkylcarbonyl, alkylcarbonylalkyl, alkylcarbonyloxy, alkylthio, alkynyl, carboxy, carboxyalkyl, cyano, cyanoalkyl, cycloalkyl, cycloalkylalkyl, formyl, formylalkyl, haloalkoxy, haloalkyl, haloalkylthio, halogen, hydroxy, hydroxyalkyl, mercapto, mercaptoalkyl, nitro, (CF 3 ) 2 (HO)C—, —NR A S(O) 2 R B , —S(O) 2 OR A , —S(O) 2 R B ,—NZ A Z B , (NZ A Z B )alkyl, (NZ A Z B )alkylcarbonyl, (NZ A Z B )carbonyl, (NZ A Z B )carbonylalkyl, or (NZ A Z B )sulfonyl, (NZ A Z B )C(═NH)—, (NZ A Z B )C(═NCN)NH—, or (NZ A Z B )C(═NH)NH—;

R A is hydrogen or alkyl;

R B is alkyl, aryl, or arylalkyl;

R 8a is hydrogen or alkyl; and

R 8b is absent, hydrogen, alkoxy, alkoxycarbonylalkyl, alkyl, alkylcarbonyloxy, alkylsulfonyloxy, halogen, or hydroxy;

provided that R 8b is absent when X 5 is N.